Drugmakers paid millions to Mass. health providers

Massachusetts just released more fodder for the doctor-payment data crunchers. As the Boston Globe reports, the state posted online the country's most comprehensive state database of healthcare payments from pharma and device makers. The data encompasses payments to doctors, like other reports we've seen, but also includes hospitals, nurses, pharmacists and other healthcare providers.

Of the $35.7 million in payments made from July 1 through December 31, 2009, some $16.4 million went to doctors, the database shows. The numbers were collected because of a 2008 law that required drug and device makers to report payments of $50 or more (and also banned gifts and limited free meals).

Drugmakers who made the top 10, payment-wise, are Eli Lilly ($LLY), with $1.7 million distributed to 259 recipients; Genzyme ($GENZ), with $1.4 million and 71 recipients; Pfizer ($PFE), with $1.34 million and 525 recipients; Forest Laboratories ($FRX) with $1.27 million and 265 recipients; The Medicines Company ($MDCO), with $1.23 million and 17 recipients; GlaxoSmithKline ($GSK) with $1.07 million and 215 recipients; Sanofi-Aventis ($SNY) with $1.04 million and 372 recipients; and Allergan ($AGN), with $966,616 and 80 recipients. There's quite a range of average payments, from $72,592 on the high side from Medicines Co. to $2,548 on the low side, from Pfizer.

- read the Globe story
- see the charts from Mass High Tech

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.